Dr. Cole on Next Steps With Tucatinib in HER2+ Breast Cancer

Publication
Video
Supplements and Featured PublicationsSABCS 2021: Updates in HER2+ Breast Cancer
Volume 01
Issue 01

In Partnership With:

John Cole, MD, chairman, Community Oncology Practices, South Shore, Ochsner Medical Center, Ochsner Health, discusses the next steps with tucatinib (Tukysa) in HER2-positive breast cancer.

The phase 3 HER2CLIMB-02 trial (NCT03975647) is currently recruiting patients with advanced or metastatic HER2-positive breast cancer to evaluate the efficacy of ado-trastuzumab emtansine (T-DM1; Kadcyla) plus tucatinib vs T-DM1 alone. However, the results of this study may be difficult to integrate into clinical practice given the positive results of the phase 3 DESTINY-Breast03 trial (NCT03529110), which ​were presented during the 2021 San Antonio Breast Cancer Symposium. The findings demonstrated that fam-trastuzumab deruxtecan-nxki (Enhertu) elicited superior efficacy vs T-DM1 as second-line therapy for patients with HER2-positive metastatic breast cancer.

Knowledge of tucatinib remains limited as the agent is relatively new, so significant research is needed to determine whether tucatinib-based combinations will be more effective vs single-agent tucatinib, Cole explains. Moreover, it will be important to evaluate whether the combinations yield acceptable toxicities and efficacy that outweighs sequential therapy, Cole concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS